| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
27,030,000 |
| Market
Cap: |
122.99(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.68 - $13.05 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VistaGen Therapeutics is a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company engaging in the treatment for individuals living with anxiety, depression and other CNS disorders. Co.'s product candidates include: PH94B, which is a synthetic investigational pherine nasal spray with a mechanism of action (MOA) that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic autonomic nervous system; and PH10, which is a synthetic investigational pherine nasal spray with a rapid-onset potential MOA that is fundamentally differentiated from the MOA of existing approved treatments for depression disorders.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
775,756 |
1,875,756 |
| Total Buy Value |
$0 |
$0 |
$17,961,079 |
$18,150,929 |
| Total People Bought |
0 |
0 |
1 |
4 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
60,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$53,400 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dotson Jerrold Duane |
VP, CFO AND SECRETARY |
• – – |
2021-09-07 |
4 |
S |
$3.13 |
$93,750 |
D/D |
(30,000) |
72,786 |
|
49% |
|
| Snodgrass H. Ralph |
PRES./CHIEF SCIENTIFIC OFFICER |
• – – |
2021-09-02 |
4 |
GA |
$0.00 |
$0 |
D/D |
1,111 |
61,335 |
|
- |
|
| Snodgrass H. Ralph |
PRES./CHIEF SCIENTIFIC OFFICER |
• – – |
2021-08-23 |
4 |
GD |
$0.00 |
$0 |
I/I |
740 |
33,901 |
|
- |
|
| Snodgrass H. Ralph |
PRES./CHIEF SCIENTIFIC OFFICER |
• – – |
2021-08-17 |
4 |
B |
$2.73 |
$10,238 |
I/I |
3,750 |
34,641 |
0.01 |
-27% |
|
| Dotson Jerrold Duane |
VP, CFO AND SECRETARY |
• – – |
2021-06-30 |
4 |
OE |
$0.40 |
$84,328 |
D/D |
89,742 |
102,786 |
|
- |
|
| Dotson Jerrold Duane |
VP, CFO AND SECRETARY |
• – – |
2021-06-30 |
4 |
A |
$1.95 |
$5,925 |
D/D |
3,044 |
13,044 |
|
- |
|
| Singh Shawn |
CHIEF EXECUTIVE OFFICER |
• • – |
2021-06-30 |
4 |
A |
$1.95 |
$9,733 |
D/D |
5,000 |
45,375 |
|
- |
|
| Smith Mark Alan |
CHIEF MEDICAL OFFICER |
• – – |
2021-06-30 |
4 |
A |
$1.95 |
$4,399 |
D/D |
2,260 |
12,260 |
|
- |
|
| Snodgrass H. Ralph |
PRES./CHIEF SCIENTIFIC OFFICER |
• – – |
2021-06-30 |
4 |
A |
$1.95 |
$6,601 |
D/D |
3,391 |
91,115 |
|
- |
|
| Singh Shawn |
CHIEF EXECUTIVE OFFICER |
• • – |
2021-04-23 |
4 |
OE |
$1.50 |
$7,500 |
D/D |
5,000 |
40,375 |
|
- |
|
| Saxe Jon S |
|
– • – |
2021-03-19 |
4 |
OE |
$1.50 |
$3,750 |
D/D |
2,500 |
5,751 |
|
- |
|
| Underdown Brian J. |
|
– • – |
2021-03-19 |
4 |
OE |
$1.50 |
$3,750 |
D/D |
2,500 |
2,500 |
|
- |
|
| Saxe Jon S |
|
– • – |
2020-08-21 |
4 |
B |
$0.69 |
$20,700 |
I/I |
30,000 |
50,000 |
0.01 |
198% |
|
| Smith Mark Alan |
CHIEF MEDICAL OFFICER |
• – – |
2020-06-30 |
4 |
A |
$0.45 |
$2,240 |
D/D |
5,000 |
5,000 |
|
- |
|
| Singh Shawn |
CHIEF EXECUTIVE OFFICER |
• • – |
2020-06-30 |
4 |
A |
$0.45 |
$2,240 |
D/D |
5,000 |
30,375 |
|
- |
|
| Dotson Jerrold Duane |
VP, CFO AND SECRETARY |
• – – |
2020-06-30 |
4 |
A |
$0.45 |
$2,240 |
D/D |
5,000 |
5,000 |
|
- |
|
| Snodgrass H. Ralph |
PRES./CHIEF SCIENTIFIC OFFICER |
• • – |
2020-06-30 |
4 |
A |
$0.45 |
$2,240 |
D/D |
5,000 |
67,724 |
|
- |
|
| Saxe Jon S |
|
– • – |
2019-03-14 |
4 |
B |
$1.27 |
$10,086 |
I/I |
7,920 |
20,000 |
0.01 |
- |
|
| Snodgrass H. Ralph |
PRES./CHIEF SCIENTIFIC OFFICER |
• • – |
2019-03-13 |
4 |
OE |
$1.50 |
$3,750 |
D/D |
2,500 |
62,724 |
|
- |
|
| Saxe Jon S |
|
– • – |
2019-03-13 |
4 |
B |
$1.26 |
$15,201 |
I/I |
12,080 |
12,080 |
0.01 |
- |
|
| Saxe Jon S |
|
– • – |
2019-01-29 |
4 |
OE |
$1.50 |
$2,063 |
D/D |
1,375 |
3,251 |
|
- |
|
| Singh Shawn |
CHIEF EXECUTIVE OFFICER |
• • – |
2019-01-14 |
4 |
OE |
$1.50 |
$38,063 |
D/D |
25,375 |
25,375 |
|
- |
|
| Gin Jerry B |
|
– • – |
2017-05-31 |
4 |
B |
$0.00 |
$0 |
I/I |
100,000 |
100,000 |
2.02 |
- |
|
| Singh Shawn |
CHIEF EXECUTIVE OFFICER |
• • – |
2016-02-12 |
4 |
A |
$0.00 |
$0 |
I/I |
5,625 |
26,234 |
|
- |
|
| Singh Shawn |
CHIEF EXECUTIVE OFFICER |
• • – |
2013-12-20 |
4 |
A |
$0.00 |
$0 |
I/I |
100,000 |
100,000 |
|
- |
|
70 Records found
|
|
Page 2 of 3 |
|
|
0.04 (0.87%) 
